Showing results (121-130 of 143) with videos related to

Sort By:
Pageof 15
BMC Endocrine Disorders|July 31, 2009
Actos Now for the prevention of diabetes (ACT NOW) studyRalph A Defronzo, Maryann Banerji, George A Bray, et al.
Nature Reviews. Disease Primers|May 19, 2016
Type 2 diabetes mellitusRalph A DeFronzo, Ele Ferrannini, Leif Groop, et al.
Food & Function|November 25, 2017
A pilot study on clinical pharmacokinetics and preclinical pharmacodynamics of (+)-epicatechin on cardiometabolic endpointsAldo Moreno-Ulloa, Nayelli Nájera-García, Marcela Hernández, et al.
The Journal of Clinical Investigation|March 12, 2011
Increased SRF transcriptional activity in human and mouse skeletal muscle is a signature of insulin resistanceWanzhu Jin, Allison B Goldfine, Tanner Boes, et al.
The New England Journal of Medicine|September 14, 2017
Effects of Sotagliflozin Added to Insulin in Patients with Type 1 DiabetesSatish K Garg, Robert R Henry, Phillip Banks, et al.
The Journal of Clinical Endocrinology and Metabolism|March 17, 2016
Diabetes Incidence and Glucose Tolerance after Termination of Pioglitazone Therapy: Results from ACT NOWDevjit Tripathy, Dawn C Schwenke, MaryAnn Banerji, et al.
Nature|April 24, 2012
A PPARγ-FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasisJohan W Jonker, Jae Myoung Suh, Annette R Atkins, et al.
The Journal of Clinical Endocrinology and Metabolism|June 16, 2005
Pancreastatin: multiple actions on human intermediary metabolism in vivo, variation in disease, and naturally occurring functional genetic polymorphismDaniel T O'Connor, Peter E Cadman, Clayton Smiley, et al.
Diabetes Care|April 8, 2014
Baseline adiponectin levels do not influence the response to pioglitazone in ACT NOWDevjit Tripathy, Stephen C Clement, Dawn C Schwenke, et al.
Pageof 15